CSG / BERLIN · PART OF ATHAGORAS GROUP

We bend the
arc of evidence
toward approval.

A Berlin-based Full-Service CRO embedded within the 500+ expert network of the Athagoras group. Ten stages, one continuous curve — from your first idea to the moment a regulator says yes and a patient gets better.

25+Years D-A-CH
500+Expert Network
10Stages
1Single Point of Contact
SCROLL
STAGE 01 · STUDY CONCEPT

The foundation of every successful trial.

Studienkonzept

Strategic goals translated into research questions. A rigorous concept that defines the scientific and regulatory pathway, determines feasibility, and shapes timeline and budget for everything that follows.

Strategy → ready-for-submissionTypical duration
Interdisciplinary: clinicians, biostatisticians, PM, RA, market accessWho leads
01
SCENE 01STUDY CONCEPT
01
STAGE 02 · PROTOCOL DEVELOPMENT

Protocol writing to EMA, BfArM and FDA standards.

Protokollentwicklung

Comprehensive protocol, patient information and consent forms, Investigator Brochure, Case Report Forms, IMPD documentation — medical writing prepared for every reviewer your study will encounter.

Typically 4–10 weeksTypical duration
Senior Medical WriterWho leads
02
PROTOCOL v1.0READY
SCENE 02PROTOCOL DEVELOPMENT
02
STAGE 03 · REGULATORY & ETHICS

BfArM · PEI · EMA · FDA — fluent in every dialect.

Regulatory & Ethik

Scientific advice and protocol assistance, Clinical Trial Application filing, Ethics Committee submissions and IMPD preparation. Regulatory roadmap mapped from the start, not retrofitted.

6–14 weeksTypical duration
Regulatory Affairs leadWho leads
03
BfArMPEIEMAFDAG-BAECMDRIVDR
SCENE 03REGULATORY & ETHICS
03
STAGE 04 · PATIENT RECRUITMENT

IMC Clinicon analytics. Realistic timelines.

Patientenrekrutierung

Feasibility analysis and site identification using IMC Clinicon site analytics, realistic recruitment timeline estimation, and competitive landscape intelligence — backed by our D-A-CH CRA network.

6–12 weeks of planning · then liveTypical duration
Project ManagerWho leads
04
D · A · CH
SCENE 04PATIENT RECRUITMENT
04
STAGE 05 · PROJECT MANAGEMENT

Single Point of Contact. No fragmentation. No delays.

Projektmanagement

The SPOC model — one dedicated Project Manager as your central hub for study sites, service providers, regulatory authorities, and your internal team. Flat hierarchies streamline bureaucratic processes. Decisions get made fast.

Whole studyTypical duration
Dedicated Project Manager (SPOC)Who leads
05
SPOCSITESVENDORSREGETHICSSPONSORTEAM
SCENE 05PROJECT MANAGEMENT
05
STAGE 06 · MONITORING

Hybrid and fit-for-purpose, per ICH-GCP E6(R3).

Monitoring

On-site Source Data Verification, remote EDC review, and Risk-Based Monitoring blended into one strategy. Maximum oversight, optimised resources — effort focused where risk is highest.

Whole studyTypical duration
D-A-CH CRA NetworkWho leads
06
ICH-GCP E6(R3) · RBM · SDV
SCENE 06MONITORING
06
STAGE 07 · DATA MANAGEMENT

Full pipeline. Zero compromise.

Datenmanagement

From first patient entry to submission-ready delivery — Remote Data Capture via Oracle Clinical RDC, hybrid CRF approaches, integrated ePRO and eDiary, GAMP 5 / 21 CFR Part 11 / Annex 11 / EMA/INS/GCP/112288/2023 / GDPR compliant.

Build 6–10w · Live: whole studyTypical duration
Head of Data ManagementWho leads
07
SUBJIDVISITPARAMVALUES-1000V1HR60.0S-1007V2SBP63.7S-1014V3TEMP67.4S-1021V4BMI71.1S-1028V1HR74.8S-1035V2SBP78.5S-1042V3TEMP82.2
SCENE 07DATA MANAGEMENT
07
STAGE 08 · BIOSTATISTICS

Built in early — not bolted on late.

Biostatistik

Biostatisticians from the first protocol discussion: sample size, power, randomisation, endpoints. A comprehensive SAP fully compliant with ICH E9 — pre-specified, audit-proof, submission-ready.

8–16 weeksTypical duration
Principal BiostatisticianWho leads
08
SAS® · ICH E9 · CDISC
SCENE 08BIOSTATISTICS
08
STAGE 09 · PHARMACOVIGILANCE

PSUR · PBRER · DSUR. QPPV in-house.

Pharmakovigilanz

SAE management, SUSAR reporting, RMP creation and updates, signal detection, DSMB participation. Materiovigilance for MedTech (PMCF · PMS · FSCAs · PRRC under MDR).

Whole study + lifecycleTypical duration
QPPVWho leads
09
PSUR · DSUR · QPPV
SCENE 09PHARMACOVIGILANCE
09
STAGE 10 · REAL-WORLD EVIDENCE

When market approval is the beginning — not the end.

Real World Evidence

NIS, PASS, PAES, PMS, label updates. RWE strategy, registries, AbD (§35a SGB V), Erprobungsstudien (§137e SGB V). Health Care Research · Patient Preferences · Clinical Pathways.

Lifecycle horizonTypical duration
RWE LeadWho leads
10
NISPASSPMSAbD§137eSmartCareRWE
SCENE 10REAL-WORLD EVIDENCE
10
WHY CSG

Small enough to be agile.
Rooted deep enough to matter.
Large enough to handle anything.

01 / SPOC

Single Point of Contact

One dedicated PM for every project — no fragmentation, no delays.

02 / FLEXIBLE

Full-Service or FSP

Engagement tailored to your needs — from a single workstream to a whole study.

03 / REGULATORY

Regulatory Expertise

BfArM · PEI · EMA · FDA · G-BA · MDR — fluent in every dialect.

04 / CRO

CRO Expertise

Phase II–IV · CE-Mark · §137e · DiGA · AbD · RWD — the full evidence stack.

05 / QUALITY

Quality First

ICH-GCP E6(R3) · MDR · GDPR compliant

25+Years D-A-CH Experience
500+Expert Network · athagoras Group
1–90Sites · from boutique to nationwide
— START THE CONVERSATION

Ready to sketch
the arc of your trial?

Lots of engagements start with a 30-minute call. By the end of it you'll have a feasibility view, a regulatory roadmap, and a named PM.

Send a one-paragraph brief →